Elevated blood pressure (BP) is an important public health concern. It is highly prevalent,
the prevalence may be increasing, and it is a risk factor for several adverse health
outcomes, especially coronary heart disease, stroke, heart failure, chronic kidney disease,
and decline in cognitive function. The Systolic Blood Pressure Intervention Trial (SPRINT) is
a 2-arm, multicenter, randomized clinical trial designed to test whether a treatment program
aimed at reducing systolic blood pressure (SBP) to a lower goal than currently recommended
will reduce cardiovascular disease (CVD) risk.
Phase:
N/A
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute of Neurological Disorders and Stroke (NINDS) National Institute on Aging (NIA) Wake Forest University Health Sciences